The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway by Chen, Zhao et al.
doi:10.1182/blood-2007-02-071589






Adelstein, Donald Ingber, George Q. Daley and Ramesh A. Shivdasani
Zhao Chen, Olaia Naveiras, Alessandra Balduini, Akiko Mammoto, Mary Anne Conti, Robert S.
 
biogenesis modulated by the Rho-ROCK pathway
 is a negative regulator of plateletMYH9The May-Hegglin anomaly gene 
 http://bloodjournal.hematologylibrary.org/content/110/1/171.full.html
Updated information and services can be found at:
 (1930 articles)Signal Transduction   
 (2494 articles)Hemostasis, Thrombosis, and Vascular Biology   
 (3207 articles)Hematopoiesis and Stem Cells   
 (143 articles)Cytoskeleton   
Articles on similar topics can be found in the following Blood collections
 http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
 http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
 http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
 Copyright 2011 by The American Society of Hematology; all rights reserved.
Washington DC 20036.
by the American Society of Hematology, 2021 L St, NW, Suite 900, 





 For personal use only.2014. 
 at ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE on March 25,bloodjournal.hematologylibrary.orgFrom 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet
biogenesis modulated by the Rho-ROCK pathway
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The gene implicated in the May-Hegglin
anomaly and related macrothrombocyto-
penias, MYH9, encodes myosin-IIA, a pro-
tein that enables morphogenesis in di-
verse cell types. Defective myosin-IIA
complexes are presumed to perturb
megakaryocyte (MK) differentiation or
generation of proplatelets. We observed
that Myh9/ mouse embryonic stem (ES)
cells differentiate into MKs that are fully
capable of proplatelet formation (PPF). In
contrast, elevation of myosin-IIA activity,
by exogenous expression or by mimick-
ing constitutive phosphorylation of its
regulatory myosin light chain (MLC), sig-
nificantly attenuates PPF. This effect oc-
curs only in the presence of myosin-IIA
and implies that myosin-IIA influences
thrombopoiesis negatively. MLC phos-
phorylation in MKs is regulated by Rho-
associated kinase (ROCK), and consis-
tent with our model, ROCK inhibition
enhances PPF. Conversely, expression of
AV14, a constitutive form of the ROCK
activator Rho, blocks PPF, and this effect
is rescued by simultaneous expression of
a dominant inhibitory MLC form. Hemato-
poietic transplantation studies in mice
confirm that interference with the puta-
tive Rho–ROCK–myosin-IIA pathway se-
lectively decreases the number of circulat-
ing platelets. Our studies unveil a key
regulatory pathway for platelet biogen-
esis and hint at Sdf-1/CXCL12 as one pos-
sible extracellular mediator. The unex-
pected mechanism for Myh9-associated
thrombocytopenia may lead to new
molecular approaches to manipulate
thrombopoiesis. (Blood. 2007;110:
171-179)
© 2007 by The American Society of Hematology
Introduction
MYH9 encodes myosin-IIA, a nonmuscle myosin heavy chain that
assembles within actomyosin complexes and facilitates shape
changes in diverse cell types.1-3 Patients with autosomal dominant
inherited MYH9-related disorders,4-6 including the May-Hegglin
anomaly,7,8 exhibit macrothrombocytopenia and variable degrees
of hearing loss, nephritis, and cataracts. These individuals experi-
ence mild bleeding symptoms as a result of reduced numbers of
misshapen blood platelets that can be 2 to 5 times larger than
normal.9,10 In the May-Hegglin anomaly, macrothrombocytopenia
is due to a defect in platelet release by megakaryocytes (MKs) in
the bone marrow, but platelets that do form seem to circulate and
function normally.9-11 The MYH9-associated syndromes are thus
regarded as disorders of thrombopoiesis,12 and defective myosin-
IIA complexes are presumed to perturb some aspect of MK
differentiation, likely late in the course of cell maturation.
Polyploid MKs accumulate an enormous and complex cyto-
plasm before they assemble and release blood platelets. Two key
processes are thought to govern the timing and execution of
platelet release. Mature MKs travel within the bone marrow and
come to lie close to sinusoidal vessels13; this process responds to
cellular and humoral interactions, mediated in part by the
chemokine stromal cell–derived factor 1 (Sdf-1 or CXCL12).14-16
In their final stages, MKs extend long cytoplasmic projections
called proplatelets and actively assemble nascent platelets at the
tips of these structures.17-19 Proplatelet formation (PPF) is
preceded and accompanied by characteristic changes in cell
shape, reorganization of the actin and microtubule cytoskel-
etons, and generation of intracellular force.20
As an abundant motor protein within MKs and the only
representative of its family,21 myosin-IIA is a good candidate
mediator of proplatelet extension or platelet release. Biochemical
studies suggest that certain N-terminal mutations found in patients
with MYH9-related disorders reduce intrinsic ATPase activity,22
whereas other common C-terminal mutations may compromise
myosin filament formation.23 Although both classes of mutations
may interfere with myosin-IIA function, it is unclear whether
monoallelic MYH9 mutations produce clinical phenotypes as a
result of haploinsufficiency or dominant-negative effects. The role
of myosin-IIA in platelet assembly and release is hence uncertain.
Conventional myosin-II complexes contain a dimer of heavy
chains, each associated with the myosin regulatory light chain
(MLC). Phosphorylated MLC enhances actin-dependent myosin
motor activity,24 and 3 kinases can phosphorylate MLC: Rho-
associated kinase (ROCK), myosin light chain kinase (MLCK),
and p21-activated kinase.24 Both ROCK and MLCK participate in
platelet activation,25-27 but their roles in MK maturation or platelet
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biogenesis are unknown. Other advances point to the important
contribution of the small-GTPase Rho in elongation and retraction
of neurites in response to Sdf-1,28,29 and morphologic similarities
between neurite extension and PPF raise the possibility that Rho
and ROCK also regulate PPF. Our investigation of mechanisms in
MYH9-related disorders led to consideration of the role of ROCK
in myosin-IIA regulation and suggested this possibility indepen-
dently. Here, we describe studies that implicate a Rho–ROCK–
MLC–myosin-IIA pathway as a negative regulator of platelet
biogenesis and suggest a surprising explanation for compromised
thrombopoiesis in the face of Myh9 gene mutations.
Materials and methods
Reagents and plasmids
Enzyme inhibitors Y-27632, ML-7, and blebbistatin were purchased from
Sigma-Aldrich (St Louis, MO), Sdf-1 from Peprotech (Rocky Hill, NJ),
MLC antibody from Sigma-Aldrich, and myosin-IIA antibodies from BTI
(Stoughton, MA) and Covance (Princeton, NJ). Human MYH9 full-length,
R1933X, and rod-domain cDNAs were cloned into BglII and EcoRI sites of
the pMIB vector, which was constructed by replacing the internal ribosome
entry site (IRES)-green fluorescent protein (GFP) fragment in pMIG (gift
from D.G. Tenen, Harvard Institute of Medicine, Boston, MA) with
IRES-Blasticidin using EcoRI and ClaI sites. GFP-fused forms were
prepared by cloning cDNAs into pEGFP-C1 (Clontech, Palo Alto, CA),
followed by subcloning into AgeI and EcoRI sites of a modified pMSCV
vector (Clontech), replacing the PGK promoter and puromycin-resistance
cassette. GFP-fused chicken D18D19-MLC and human A18A19-MLC and
D18D19-MLC were excised from pEGFP-N1 host vectors (Clontech) and
subcloned into BglII and ClaI sites of pMIG, replacing the IRES-GFP
cassette. Red fluorescent protein (RFP)–fused MLC mutants were cloned
into dsRed2-N1 (Clontech), and then ligated into BglII and ClaI sites of
pMIG depleted of the IRES-GFP cassette. RhoAv14 was cloned by
polymerase chain reaction (PCR) amplification and introduced into BglII
and EcoRI sites of pMIG.
Tissue and ES cell culture
MKs were cultured and purified as described previously.30 Human umbili-
cal vein endothelial cells (HUVEC) were cultured in EBM-2 medium
(Cambrex, Baltimore, MD) at 37°C in 5% CO2 atmosphere. MYH9/ ES
cells were generated by re-electroporation of MYH9/ embryonic stem
(ES) cells with the targeting construct31 and selection of colonies at
increased G418 concentration (2.5 mg/mL). MKs were differentiated from
mouse ES cells with minor modification of published methods.32,33 Briefly,
2  104 ES cells were cultured in -Minimal Essential Medium (MEM)
(Invitrogen, Carlsbad, CA) over a monolayer of OP9 stromal cells (gift
from S. Shattil, University of California, San Diego, CA) that was plated
2 days earlier in -MEM medium supplemented with 20% fetal bovine
serum (FBS) (Gemini, Alachua, FL). Differentiation took place for 5 days
before ES cell derivatives were transferred onto a fresh OP9 monolayer in
-MEM medium supplemented with 15% FBS (Stem Cell Technologies,
Vancouver, BC, Canada) and 1% thrombopoietin (TPO)–conditioned
medium.34 Differentiation was continued for 3 additional days before cells,
including MKs, were transferred to a layer of -irradiated (3000 cGy) S17
stromal cells (gift from K. Akashi, Dana-Farber Cancer Institute, Boston,
MA). PPF was scored on days 9 through 11, counting the initiation of ES
cell differentiation as day 0. PPF was scored using the following criteria
(see Figure S6, available on the Blood website; see the Supplemental
Materials link at the top of the online article): (1) MKs lacking filaments,
even those with shape change or short buds, were regarded as PPF-negative;
(2) typical PPF MKs are characterized by extension of multiple proplate-
lets, with the most filaments exceeding 10 m in length; (3) abnormal PPF
MKs were judged by the presence of small or dense clusters surrounding the
cell body; however, MKs with 3 or more extended proplatelets were
counted as typical PPF even if clustered filaments were also evident.
Hematopoietic transplantation and flow cytometry
C57BL6/J bone marrow was treated with RBC lysis buffer (Sigma-
Aldrich), followed by negative selection with magnetic beads (Miltenyi,
Auburn, CA) and phycoerythrin (PE)–conjugated lineage-specific antibod-
ies (Gr1, B220, CD4, CD8, NK1.1, Ter119) to enrich for progenitors.
Isolated cells were transduced with retrovirus once every 24 hours for
3 days in StemSpam media (Stem Cell Technologies) in the presence of
stem cell factor, TPO, interleukin-11 (IL-11), and IL-6 (Peprotech). For
fetal liver transplantation, livers were isolated from embryonic day 13.5
(E13.5) mouse embryos and transduced with retrovirus as with Lin bone
marrow progenitors. Six- to 10-week-old C57BL/6J female mice were
given 2 doses of 550-cGy -irradiation separated by 3 hours, followed by
retro-orbital sinus coinjection of retrovirus-transduced hematopoietic pro-
genitors and 1.5  105 helper bone marrow mononuclear cells from
age-matched C57BL6/J females. Mice were kept in a sterile environment
for 6 weeks, with retro-orbital sinus blood sampling between 3 and 6 weeks,
followed by euthanasia to analyze spleen and bone marrow. Total engraft-
ment was evaluated as GFP cells within the CD45 fraction, and
multilineage engraftment as GFP cells in the myeloid Gr1Mac1 and
lymphoid CD3CD19 compartments. Donor-derived MKs and platelets
were identified on the basis of GFPCD61 signals in blood, spleen, or
marrow samples that were disaggregated, diluted, and stained in acid citrate
dextrose buffer, as described elsewhere.35 All antibodies were purchased
from BD Biosciences (San Diego, CA) and flow cytometry was performed
in a BD Biosciences FACSCalibur instrument. Studies were approved by
institutional animal care committees.
Retroviral infection
Retroviruses were produced by cotransfecting viral and PCL helper
plasmids36 into 50% to 70% confluent 293T cells using Fugene-6 (Roche,
Palo Alto, CA). Medium was changed 24 hours later, and viral supernatants
were harvested at 48 and 72 hours. Fetal liver cells were cultured with
TPO-conditioned medium overnight before exposure to viral supernatants
in the presence of 8g/mL polybrene (Sigma-Aldrich) by centrifugation at
800g at 25°C for 90 minutes and incubation at 37°C for 1.5 hours. Cells
were cultured in fresh TPO-conditioned medium for 2 days before isolation
of advanced MKs over a bovine serum albumin (BSA) step-gradient30 for
further analysis. ES cell–derived hematopoietic progenitors were infected
similarly on differentiation day 5 before transfer onto fresh OP9 stromal
cells. HUVEC, COS-7, MCF-7, and NIH3T3 cells were infected by
overnight incubation with viral supernatants at 37°C in the presence of
6 g/mL polybrene. For long-term cultures, ES cells were selected in
10 g/mL blasticidin (Invitrogen).
Immunostaining and fluorescence microscopy
Mouse MKs and platelets were prepared and stained as described previously37;
other cells were grown on glass coverslips before fixation and staining. Actin
stress fibers were visualized after staining with Alexa 594–conjugated phalloidin
(Molecular Probes, Eugene, OR). Deconvolution microscopy followed previous
description.37 Slides were mounted with Fluoromount-G (Southern Biotech,
Birmingham, AL) and examined on an Olympus (Melville, NY) IX70 inverted
fluorescence microscope, using 60 (Olympus PLAN-APO 1.40 NA, 0.10 mm
WD) or 100 (PLAN-APO 1.40NA, 0.10 mm WD) oil objectives or 40/1.35
NA or 20/0.50 plain objectives. Images were acquired with a CM350 CCD
camera (Applied Precision, Issaquah, WA) using DeltaVision software (Applied
Precision). Live cells were imaged using a Nikon Eclipse TE300 inverted
fluorescent microscope with Nikon 10/0.30 or 20/0.45 plain objectives.
Images acquired by a Spot camera (Diagnostic Instruments, Sterling Heights,
MI) with software version 4.0.9. All images were taken at ambient temperature
and processed with Photoshop 7.0 software (Adobe Systems, San Jose, CA).
Rho activity
Rho activity was assayed using a kit based on rhotekin precipitation
(Cytoskeleton, Denver, CO) according to the manufacturer’s instruction.
Briefly, 1.5  106 cells were washed with phosphate-buffered saline and
172 CHEN et al BLOOD, 1 JULY 2007  VOLUME 110, NUMBER 1
 For personal use only.2014. 
 at ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE on March 25,bloodjournal.hematologylibrary.orgFrom 
protein was extracted in 300 L lysis buffer (25 mM Tris [tris(hydroxy-
methyl)aminomethane] [pH 7.5], 150 mM NaCl, 5 mM MgCl2, 1% Triton
X-100). Samples were centrifuged for 5 minutes at 5000g and the
supernatant was incubated with rhotekin beads for 1.5 hours at 4°C. After
washing the beads with buffer (25 mM Tris [pH 7.5], 40 mM NaCl, 15 mM
MgCl2), proteins were removed in Laemmli buffer and analyzed by
immunoblotting. The ratio of rhotekin-bound RhoA and total cellular RhoA
was determined using NIH Image software.
CFU-C assay of ES-derived hematopoietic progenitors
Embryoid bodies (EB) were generated from ES cells as hanging drops, as
described elsewhere38 and disaggregated on the sixth culture day. To
evaluate the potential of day 6 EB-derived cells to form colonies in
methylcellulose, 5  104 cells were plated in cytokine-enriched methylcel-
lulose (M3434; Stem Cell Technologies). Erythroid (E), granulocyte (G),
macrophage (M), mixed (GM), and multilineage (GEMM) colony-forming
units (CFU) were counted 8 days later.
Results
Localization of myosin-IIA and differentiation of MYH9
nullizygous ES cells
To elucidate myosin-IIA functions in thrombopoiesis, first we
examined its subcellular localization in terminally mature MKs
cultured from wild-type mice. Myosin-IIA was distributed uni-
formly throughout the cytoplasm, without obvious association with
recognized structures. Although some cells showed apparent
concentration at the cell periphery (Figure 1A), no further organiza-
tion was evident. Exogenous GFP-fused myosin-IIA expressed in
cultured MKs showed identical localization and seemed to function
normally, as judged by association with actomyosin filaments in
COS7, MCF-7, NIH3T3, and HUVEC cells (data not shown).
Myosin-IIA distribution remained diffuse in MKs displaying PPF
(Figure 1B-C), except at the tips of proplatelets, where it showed a
reticular organization within the cytoplasm (Figure 1D). Although
this pattern resembles that observed in blood platelets (Figure 1E),
myosin-IIA distribution within MKs does not shed light on
potential mechanisms in platelet release.
Early lethality of Myh9/ embryos31 limits in vivo investiga-
tion of the role of myosin IIA in thrombopoiesis. We therefore
introduced GFP-encoding retroviruses into mouse ES cells and
differentiated them toward the MK lineage in the presence of TPO
and stromal cell support.32,33 Myh9/ ES cells showed robust
hematopoietic and MK differentiation, indistinguishable from
Myh9/ ES cells, and because Myh9/ cells were derived from
Myh9/ clones, the latter served as the control of choice. Myh9/
ES cells resisted differentiation, as reflected in increased formation
of secondary embryoid bodies and reduced numbers of multipoten-
tial hematopoietic progenitors (Figure S1A). Nevertheless, MKs
that did derive from Myh9/ ES cells showed no overt matura-
tional defects and generated apparently normal proplatelets (Figure
2A-C). Myh9/ MKs also released platelet-like particles effi-
ciently into the culture medium (Figure 2D-E). We confirmed that
myosin-IIA is the only myosin-II isoform expressed in ES cell–
derived MKs (data not shown), as demonstrated previously in bone
marrow MKs.21 Thus, substitution by close homologs cannot
account for the unexpected finding that myosin-IIA is dispensable
for MK differentiation and PPF.
The limited numbers of MKs derived from Myh9/ cultures
and their tendency to adhere to stromal cells (Figure 2C) made it
difficult to acquire and interpret DNA ploidy data, but their PPF
capacity implies that endomitosis is largely unaffected. Platelet-
like particles released by Myh9/ MKs varied substantially in size
and shape (Figure S1C), and 21% to 41% of particles released by
wild-type fetal liver–derived MKs with or without exogenous gene
expression fall outside the flow cytometry gates defined by
circulating mouse blood platelets (Figure S1D). Such heterogeneity
among platelets generated in vitro highlights the limitation of
culture systems to study platelet size, which is anomalous in
MYH9-related disorders. Our experimental models nevertheless
allow reliable investigation of many aspects of MK maturation and
platelet release.
We consistently observed that PPF in Myh9/ ES cell–derived
MKs occurs more robustly than in controls (Figure 2F pie charts).
This surprising result suggests that loss of myosin-IIA function
enhances or accelerates platelet release and that myosin-IIA may
regulate thrombopoiesis not positively but negatively. To evaluate
this possibility, we treated primary cultured MKs with blebbistatin,
a selective antagonist of myosin-II ATPase activity.39 Treatment
initiated at the start of fetal liver culture (ie, in blood progenitors)
had no effect on the usual increase in MK size or DNA content
(data not shown). However, when we exposed mature MKs to
blebbistatin, PPF frequency was substantially increased (Figure
2G), again suggesting an inhibitory role for myosin-IIA.
Modeling MYH9-related thrombocytopenia in vivo
Patients affected by autosomal dominant MYH9-related disorders
retain one normal allele; platelet defects may hence reflect gene
Figure 1. Myosin-IIA localization in mouse fetal liver–
derived mature MKs and blood platelets. (A) Merge of
actin (phalloidin, red),myosin-IIA(antibody,green),andnuclear
(DAPI [4,6-diamidino-2-phenylindole], blue) staining in a rep-
resentative mouse fetal liver–derived MK, with actin and
myosin-IIA staining shown separately in panels Aii and Aiii,
respectively. Myosin-IIA is expressed diffusely in the cyto-
plasm with slight increase at the cell cortex. (B-D) Myosin-IIA
(green) or merge of actin (C) (red) or -tubulin (D) (red) and
myosin-IIA (green) signals in mouse fetal liver–derived pro-
platelets. Myosin-IIAis expressed uniformly along the proplate-
let length, even though the increased cytoplasmic mass in
proplatelet swellings conveys the false impression that it
concentrates in these structures. Insets in panels B and C
show portions of similar proplatelets at higher magnification.
An organized reticular distribution is detected at the tips of
individual proplatelets (D), where MK microtubules form a
characteristic coil. (E) Myosin-IIA distribution in proplatelet
ends resembles that seen in blood platelets. Scale bars
represent 3 m (A), 15 m (B-C), 3 m (B-C, insets; D), and
0.5m (E).
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haploinsufficiency or dominant-negative effects of the mutant
allele. Our results with differentiated Myh9/ ES cells argue
against strict quantitative requirements for myosin-IIA; however,
the unusually high abundance and size of this protein make it
difficult to model potential dominant-negative effects of point
mutations or small deletions. In contrast, GFP-labeled rod domain
of myosin-IIA, an alternative dominant-negative form previously
characterized in Dictyostelium40 (GRD, incorporating myosin-IIA
amino acids 1338–1960), was expressed more reliably than full-
length mutants in MKs, as judged by flow cytometry (data not
shown), and immunoblot analysis of cultured MKs indicated 7-fold
average overexpression compared with endogenous myosin-IIA
(Figure S2A). We transduced wild-type mouse bone marrow cells
with GRD-encoding retrovirus and infused these cells into irradi-
ated recipient mice. Three weeks later, mice receiving GRD-
transduced marrow cells showed leukocyte engraftment levels
similar to those transplanted with GFP-transduced cells, but
approximately one-third as many GFP-positive platelets (Figure
3A). This result confirms that interference with myosin-IIA func-
tion disrupts platelet production. Wild-type fetal liver–derived
MKs expressing different myosin constructs or treated with
blebbistatin showed the typical DNA ploidy profile (data not
shown), which suggests that myosin-IIA functions are dispensable
for endomitosis.
Gain of myosin-IIA function supports an unexpected negative
role in thrombopoiesis
The broad differentiation arrest of Myh9/ ES cells (Figures S1A
and S2F) precluded stricter quantitative comparison of thrombopoi-
etic efficiency. To overcome this limitation, we cultured primary
mouse MKs to determine how gain of function or aberrant activity
of mutant myosin-IIA might affect PPF. The numbers and morphol-
ogy of proplatelets extended by cultured MKs serve as a valid
physiologic marker of platelet release19,41; 15% to 20% of large
cells usually display PPF on the fourth or fifth day after murine
fetal liver progenitors are cultured in continuous presence of
thrombopoietin.30 Expression of full-length myosin-IIA in wild-
type MKs delayed the period of peak PPF and reduced modestly
the proportion of cells that extend proplatelets (Figure 3B).
Moreover, proplatelets produced upon exogenous myosin-IIA
expression displayed a distinctive, atypical morphology; nearly
70% of proplatelet-forming MKs elaborated short grape-like
clusters in lieu of the extensive network of elongated filaments that
appeared in most GFP-expressing control MKs (Figure S2B).
These findings support the notion that myosin-IIA may act not to
enable PPF, as we and others had assumed,12 but rather to restrain
it. Low viral titers and correspondingly low transduction efficiency
precluded quantitative assessment of exogenous myosin-IIA levels
in MKs. In Myh9/ ES cells, however, the same constructs drove
expression at levels comparable with those found in uninfected
Myh9/ ES cells (Figure S2A).
Expression of the disease-associated MYH9 mutant R1933X in
cultured MKs also attenuated PPF and delivered morphologic
anomalies similar to those observed upon expression of wild-type
myosin-IIA (Figure S1C), although both effects were muted in
comparison with the wild-type form. Putative dominant-negative
myosin-IIA forms, including R1933X, can disrupt actin stress
fibers.23 Because stress fiber detection varied considerably in our
hands, even in unmanipulated wild-type MKs, we tested myosin-
IIA constructs in HUVEC, where the R1933X variant did not
disrupt actin stress fibers (Figure S3). Exogenous full-length
myosin-IIA forms may thus function unpredictably, and we opted
to study its role indirectly through its regulatory cofactors.
Regulation of myosin-IIA function in MKs
Phosphorylated myosin regulatory light chain (MLC) enhances
actin-dependent myosin motor activity24 and is thus a positive
regulator whose effects should mimic gain of myosin-IIA function.
We first used retroviral infection to express GFP-tagged wild type
MLC in cultured murine blood progenitors and the GFP signal to
Figure 2. Myosin-IIA is not required for MK maturation in vitro. (A-C) MKs
differentiated in vitro from Myh9/ ES cells. (A) A representative MK colony derived
from Myh9/ ES cells in a day 8 differentiation culture. (B) A representative
GFP-positive Myh9/ MK reveals abundant proplatelets (arrowheads); the inset at
top right shows a released proplatelet filament. (C) Phase-contrast image of a
representative proplatelet (arrowheads)–elaborating MK from similar cultures. Bars
represent 15 m. (D) Flow cytometry analysis of platelets released by MKs
differentiated from ES cells. GFP (X-axis) and CD61 (Y-axis) double-positive particles
are shown in the red scattergram bounded by the blue polygon. (E) Comparison of
platelet numbers released from Myh9/ and Myh9/ ES cell–derived MKs. Number
of particles with platelet properties detected by flow cytometry within 100-L culture
supernatants are expressed per 100 PPF MKs scored visually within the same
cultures. (F) Number of MKs derived from GFP-expressing Myh9/ and Myh9/ ES
cells on differentiation day 9. Cell numbers represent MKs derived from 2  105
progenitors collected from day 5 differentiation culture, except that Myh9/ MKs (*)
are plotted at one-tenth of the original count. The pie charts above the graph
represent the fraction of MKs forming proplatelets. PPF in all cultures and MKs in
Myh9/ samples were counted over full wells in 6-well culture dishes; Myh9/ MKs
were counted in 6 separate microscope fields and extrapolated to the total surface
area. (G) PPF efficiency of cultured primary wild-type MKs after blockade of
myosin-IIAATPase activity. Blebbistatin (100 M, prepared from a 20 mg/mL stock in
dimethyl sulfoxide [DMSO]) or DMSO was added to fetal liver cell cultures after
enrichment for MKs over a BSA step-gradient on culture day 3. PPF was assessed on
day 4 as described for panel F.
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monitor infected MKs. Exogenous wild-type MLC delayed the
onset of PPF by approximately 12 hours and proplatelet morphol-
ogy resembled that seen with exogenous myosin-IIA expression
(Figure 4A-B). Both features were more exaggerated than those
obtained with myosin-IIA (Figure S1C), probably because the
smaller gene construct size generated substantial MLC levels (data
not shown). To test myosin gain-of-function more rigorously, we
introduced a dominant-active MLC form that mimics constitutive
phosphorylation (D18D19-MLC)42,43 in hematopoietic progenitors.
GFP-fused and endogenous proteins could be resolved by gel
electrophoresis, and we used MLC immunoblotting to estimate that
exogenous proteins were represented at an average of 1.7-fold
higher level than native MLC in transduced MKs (Figure S4A).
With both chicken and human D18D19-MLC constructs, genesis and
maturation of MKs were unaffected but PPF was completely
blocked (Figure 4A-B).
GFP-fused MLC tended to accumulate in a few spots within
infected MKs (Figure 4B and data not shown). Because D18D19-
MLC associated with presumptive actomyosin bundles in adherent
fibroblasts from the same primary cultures (Figure 4C) and
blebbistatin treatment caused the GFP signal to spread throughout
the cytoplasm (data not shown), these spots likely signify regional
myosin activation. Nevertheless, to exclude nonspecific toxic
effects and, more important, to determine whether D18D19-MLC
was acting through endogenous myosin-IIA, we expressed the
constitutively active MLC (human D18D19-MLC) in Myh9/ and
control Myh9/ ES cells. GFP signals again concentrated region-
ally within ES cell–derived MKs. Whereas D18D19-MLC arrested
PPF in Myh9/ cells, similar to effects in primary wild-type MKs,
it failed to block PPF in Myh9/ MKs (Figure 4D), thus
establishing a clear link between D18D19-MLC actions and Myh9.
In a converse test, we inhibited myosin activity by introducing a
characterized, phosphorylation-resistant A18A19-MLC dominant-
negative mutant42 in primary MKs. Similar to the effect of
blebbistatin, the resulting myosin-IIA inactivation enhanced PPF
significantly (Figure 4A), and the majority of MKs elaborated a
proplatelet network considerably more extensive than seen in
typical MKs (Figure 4E). These results establish a crucial, myosin-
IIA–dependent role for MLC in regulating PPF and suggest that a
phospho-MLC–regulated pathway controls platelet release.
The Rho-associated kinase ROCK acts through MLC to
regulate PPF negatively
Both myosin light chain kinase (MLCK) and ROCK are known to
phosphorylate MLC in platelets.44,45 To determine whether they
contribute to control of PPF, we first tested the effects of the ROCK
inhibitor Y27632 and the MLCK antagonist ML-7. Whereas ML-7
did not affect PPF, Y27632 enhanced PPF considerably (Figure
Figure 3. Interference with myosin-IIA function during MK matura-
tion. (A) Bone marrow transplant evaluation of the role of myosin-
IIA in platelet production by functional dominant interference.
Control (GFP) and GFP-fused rod domain (GRD) groups represent
results from 4 or 5 independently transplanted animals, and the
differences in thrombopoietic efficiency are significant (P  .02) by
the 2-tail Student t test. (B) PPF efficiency of cultured primary
wild-type MKs expressing myosin-IIA constructs. Values are ex-
pressed as the fraction of all MKs (scored by cell size and
morphology under phase-contrast microscopy) that extend proplate-
lets. Cultures were evaluated at 84 hours (black) and 96 hours
(gray) after initiation of culture, and following enrichment for MKs
over a BSA step-gradient.
Figure 4. Myosin light chain regulates PPF negatively in a myosin-IIA–
dependent manner. (A) Constitutively activated (D18D19), dominant-negative (A18A19),
or wild-type GFP-tagged MLC constructs were introduced into fetal liver–derived
blood progenitors by retroviral transduction. Wild-type MLC significantly delayed the
onset and peak of PPF, whereas D18D19-MLC blocked PPF and A18A19-MLC
enhanced PPF less than 2-fold. (B) PPF morphology after exogenous MLC
expression. Abnormal grape-like clusters of proplatelets appeared with expression of
wild-type MLC, compared with fully extended PPF in control GFP-expressing MKs;
D18D19-MLC showed restricted localization within MKs (bright green spots) and
blocked PPF. (C) GFP-D18D19-MLC incorporates into actomyosin structures formed
within fibroblasts in the same primary cultures. (D) D18D19-MLC also blocked PPF in
MKs derived from normal ES cells (data not shown) but not in those from Myh9/ ES
cells. RFP-fused D18D19-MLC was introduced by retroviral transduction into blood
progenitors derived from GFP Myh9/ ES cells on differentiation day 5 and again
localized in a few spots within cells. A neighboring MK not expressing RFP-D18D19-
MLC is also shown (red arrowhead). Both cells show fully extended proplatelets that
appear normal. (E) A18A19-MLC enhanced PPF in wild-type MKs. MKs derived from
blood progenitors doubly transduced with GFP and RFP-A18A19-MLC generated
considerably more proplatelets than MKs expressing only GFP. All scale bars
represent 15 m.
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5A), comparable with the increase observed upon loss of myosin-
IIA activity induced by blebbistatin or A18A19-MLC. This enhance-
ment was reversed fully in MKs expressing D18D19-MLC, which
indicates that ROCK influences PPF through regulation of MLC
(Figure 5A).
In many cell types, ROCK activation is regulated by the
well-characterized small-GTPase Rho, which other groups have
previously implicated among the signals that lead up to platelet
release.46,47 We also reported that a transcriptional program associ-
ated with Rho activity peaks in expression in MKs of mid-maturity
and declines in conjunction with PPF.48 In agreement with such
results, expression of a dominant-active form of Rho (RhoAV14)
reduced PPF significantly (Figure 5B) and the ROCK inhibitor
Y27632 reversed this effect, increasing PPF levels even higher than
those in wild-type controls. By contrast, ML-7 did not affect PPF in
the context of RhoAV14, suggesting that Rho may function
specifically through ROCK to control platelet release. Neither
constitutively active nor dominant-negative forms of mDia1,
another well-known downstream Rho effector,29,49 influenced MK
maturation or PPF (data not shown). To determine whether
myosin-IIA is the principal target of Rho-ROCK signaling in
regulation of PPF, we infected primary MK cultures with separate
retroviruses to coexpress A18A19-MLC and RhoAV14 fused to red
and green fluorescent proteins, respectively. Double-fluorescent
cells displayed an average 8-fold increase in PPF compared with
MKs expressing RhoAV14-GFP alone (Figures S3 and 5B).
Activated MLC thus overrides the inhibition conferred on PPF by
RhoAV14 and indicates that MLC is a downstream effector of Rho
signaling in mature MKs. These results tightly implicate Rho and
its effector kinase ROCK in PPF, first through MLC phosphoryla-
tion and secondarily through myosin-IIA functions. The data
support a negative role for this pathway in thrombopoiesis.
In vivo confirmation of a mechanism for negative regulation
of thrombopoiesis
To assess the in vivo significance of a putative Rho–ROCK–MLC–
myosin-IIA pathway, we performed hematopoietic transplantation
assays, using GFP-fused wild-type (wt)-MLC or D18D19-MLC to
mimic gain of myosin-IIA function and RhoAV14 to perturb the
signaling pathway at a proximal point. We transduced fetal liver
cells with GFP-labeled retrovirus, infused these cells into irradiated
mice, and observed equal engraftment of GFP cells in circulating
leukocyte and bone marrow MK populations in all experimental
groups; thus, early MK differentiation is unimpaired in the
presence of mutant MLC or RhoA (Figure 5C). To assess thrombo-
poiesis, we measured the ratio of fluorescent platelets to GFP-
expressing MKs. Mice rescued with cells that express either GFP
alone or GFP-wt MLC yielded at least 1:2 ratios between fluores-
cent platelets and engrafted MKs. In contrast, cells transduced with
either dominant-active D18D19-MLC or dominant-active RhoAV14
showed few GFP-positive platelets relative to robust MK engraft-
ment in bone marrow (Figure 5D). Both D18D19-MLC (Figure 4)
and RhoAV14 (Figure 5B) blocked PPF in cultured MKs, whereas
exogenous MLC delayed but did not obviate the process (Figure
4A). Marrow transplantation results are thus fully concordant with
those from MK culture.
A candidate extracellular regulator of Rho function in MKs
Our data place myosin-IIA in a pathway that responds to external
cues and conveys signals through Rho and ROCK to restrain
platelet release. Of the many cytokines present in marrow stroma,
Sdf-1/CXCL12 is both a MK chemoattractant14-16 and a regulator
of Rho activity during neurite outgrowth,29 a process that superfi-
cially resembles PPF. To assess the plausibility of a model wherein
Figure 5. The small-GTPase Rho and its effector kinase
ROCK control platelet production in vitro and in vivo
through regulation of myosin-IIA functions. (A) MLC
phosphorylation appears to be regulated by ROCK. Kinase
inhibitors were added to primary MKs enriched over a BSA
step-gradient on day 3 of fetal liver cell culture. PPF, as-
sessed 24 hours later by the method described in Figure 2,
was enhanced by the ROCK inhibitor Y-27632 but not the
MLCK inhibitor ML-7. The effect of Y-27632 was completely
reversed upon expression of D18D19-MLC. (B) Expression of
activated Rho (RhoAV14) in MKs led to greatly reduced PPF,
which was reversed by Y-27632 or expression of dominant-
negativeA18A19-MLC, but not by ML-7. (C) Mouse transplan-
tation with blood progenitors transduced by retroviral con-
structs expressing wild-type MLC, D18D19-MLC, or RhoAV14.
Comparison of peripheral blood leukocyte engraftment and
bone marrow MK engraftment in animal groups transplanted
with cells transduced by the indicated constructs. (D)Assess-
ment of platelet production efficiency. Peripheral blood plate-
let recovery was measured 5 weeks after transplantation,
followed by euthanasia to determine bone marrow MK and
myeloid engraftment using flow cytometry. Only animals
showing less than 15% MK engraftment were included in the
analysis. Thrombopoietic efficiency is expressed as the ratio
of (GFP platelets/total platelets) to (GFP MKs/total MKs).
Statistical significance of the differences between groups
was calculated by the 2-tailed Student t test. (E) Sdf-1
attenuates endogenous RhoA activity in mature MKs. Bone
marrow–derived MKs, isolated over a BSA step-gradient 72
hours after culture initiation, were treated with 10 or 100
ng/mL recombinant Sdf-1. Activated and total Rho levels
were evaluated after 3 hours. The right panel shows a
time-course study of fetal liver–derived primary MKs treated
with 100 ng/mL Sdf-1, with determination of Rho activity
30 minutes and 3 hours later.
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Sdf-1 regulates the Rho-ROCK-myosin pathway in MKs, we
treated cultured cells from 2 different sources with recombinant
Sdf-1. Mouse bone marrow– and fetal liver–derived MKs re-
sponded to Sdf-1 with measurable reduction of cellular Rho
activity (Figure 5E). This response varied with both Sdf-1 concen-
tration and the duration of exposure.
Discussion
The functional outcome of MK maturation is the assembly and
release of thousands of blood platelets, a final step that is preceded
by obligate changes in MK shape and cytoskeletal organization.19,20
We outline a cell-intrinsic signaling pathway that seems to restrain
PPF and converges on myosin-IIA (Myh9), an abundant nonmuscle
myosin in MKs and platelets. Because myosin-II isoforms control
shape in other cell types and couple morphogenesis with cytoskel-
etal rearrangements,1-3 they are good candidates to mediate cytoskel-
etal or motor functions related to platelet release. Although it is
therefore commonly assumed that myosin-IIA enables thrombopoi-
esis,12 our data suggest that, on the contrary, myosin-IIA may act to
limit platelet release. Thus, PPF is enhanced in MKs derived from
Myh9/ ES cells, in primary MKs treated with the myosin-ATPase
inhibitor blebbistatin, and upon dominant interference with either
myosin-IIA or its regulator MLC. Most important, the phospho-
MLC–mimetic D18D19-MLC, which activates myosin,43 attenuates
PPF in cultured MKs and those differentiated from Myh9/ ES
cells but not in MKs derived from Myh9/ ES cells. These results
collectively implicate myosin-IIA and its upstream signaling
pathway in negative regulation of platelet release.
MKs are very likely to require mechanisms to avoid platelet
assembly and release until the appropriate time. Following endomi-
tosis, the MK cytoplasm gradually accumulates the many mol-
ecules and organelles that need to be packaged within each platelet;
as these components are produced asynchronously, some will
remain limiting until the cell is fully mature. Precocious platelet
assembly would result either in faulty structures with a paucity of
the limiting ingredients or, when critical material is lacking, in
MKs failing to realize their full synthetic potential. If most MKs
produce platelets prematurely, the predicted outcome is thrombocy-
topenia, and our results imply that this may be a basis for the
May-Hegglin and related MYH9-associated disorders. We suggest
that myosin-IIA is a critical element in a pathway that restrains
thrombopoiesis until MKs accumulate sufficient quantities of the
materials required to assemble platelets optimally. Sabri et al41
recently argued for a conceptually similar basis for thrombocytope-
nia associated with the Wiskott-Aldrich syndrome, where observa-
tions in mice suggested platelet release occurs in the marrow
interstitium instead of the sinusoidal vasculature.
Because platelet assembly and release are coupled processes,20
our model accounts for the heterogeneous platelet populations
observed in MYH9-related disorders: prematurely released platelets
might escape fine control over their final size, and limitation of
elements required to confer elliptical shape, such as the MK-
specific tubulin isoform 1,50 might induce spherocytosis in a
platelet subpopulation. Notably, MKs would still produce many
normal or nearly normal platelets and hemostasis may not be
significantly compromised, exactly as reported in humans with
MYH9 gene mutations. MYH9 mutations that result in either gain or
loss of function could, in principle, affect thrombopoiesis ad-
versely. Loss of myosin-IIA function could trigger PPF prema-
turely, whereas gain-of-function mutations may limit platelet
production. MYH9 mutations in humans are distributed across the
coding region and there is no correlation between genotypes and
the spectrum of clinical manifestations.21,51 Thrombocytopenia is
the one common feature among MYH9-associated disorders and it
will be interesting to study MK anomalies in relation to our model
and to specific mutations, although patient-derived materials could
be a limiting factor.
Compared with the largely invariant size distribution of normal
blood platelets, those released from cultured MKs are very
heterogeneous, even when gene expression is not manipulated. In
culture, constitutive inhibition of PPF, as we propose occurs in
vivo, is probably lacking or inefficient; accordingly, platelet release
may be generally premature and favor heterogeneity in size and
shape. Platelet size is also highly variable for several weeks after
bone marrow transplantation, even in mice receiving untransduced
cells. Although our studies provided reliable handles on PPF and
circulating platelet numbers, these features curtailed our ability to
assess platelet size, a parameter that is defective in the May-
Hegglin anomaly.
The MYH9-associated disorders, which are inherited as autoso-
mal dominant traits, must reflect either gene haploinsufficiency or
dominant-negative effects of the mutant allele. In vitro differentia-
tion of Myh9/ mouse ES cells suggest that gene dosage is
unlikely to be a limiting factor in humans but this remains formally
possible for some truncation mutants. The extreme abundance of
endogenous myosin-IIA and the technical challenges associated
with exogenous expression of common mutant forms, which are
large, make it difficult to establish the nature of likely dominant-
negative effects. We therefore used D18D19-MLC as a means to
activate myosin-IIA and then extended the studies to reveal
apparent regulation of myosin-IIA by MLC, Rho, and ROCK.
Transplantation experiments confirmed the importance of this
signaling pathway, because platelet numbers fell upon functional
interference through the myosin-IIA C-terminal rod domain (Fig-
ure 3A) and with constructs that mimic phospho-MLC or constitu-
tively active Rho (Figure 5D).
Our studies complement and extend elements of a report that
appeared while this manuscript was in preparation. Using MKs
differentiated in vitro from cord blood and adult human CD34
cells, Chang et al47 show that Rho and ROCK are negative
regulators of PPF. Their study began with assessment of Rho
activity in maturing MKs and led them to speculate that the
Rho-ROCK pathway may impinge on myosin-IIA regulation of
platelet release. By contrast, our study originated in a quest to
decipher the cellular basis of MYH9-related disorders. We used
genetic tools (Myh9-null ES cells) and exogenous gene expression
in cultured mouse MKs to infer that myosin-IIA may inhibit rather
than enable platelet release. Working from this observation, we
investigated the mechanisms that may regulate myosin-IIA motor
activity, including MLC and potential MLC kinases. Our conclu-
sions, based on precise combinations of genetic tools, exogenous
constructs, and small-molecule antagonists, argue for an inhibitory
role for the Rho–ROCK–MLC–myosin-IIA pathway in thrombopoi-
esis. The 2 reports thus reinforce each other’s conclusions and
together set the stage for further mechanistic investigation of
thrombopoietic mechanisms in general and defects underling
MYH9-related disorders in particular.
Our model emphasizes a role for continuous inhibition of PPF
during MK maturation. Factors like collagen I found in the marrow
environment may activate Rho GTPase continuously in MKs and
thus inhibit PPF. In the final maturation stage, MKs migrate to a
different niche, near vascular endothelium, where Sdf-1 and other
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factors may act to lift the restraints imposed by the Rho-ROCK-
myosin pathway and hence enable PPF (Figure S5). Signals that
trigger PPF in preterminal MKs are poorly understood, and
although there may be several, the link to Rho signaling highlights
the potential role of Sdf-1/CXCL12, a known MK chemoattrac-
tant14-16 and an extracellular ligand known to signal to Rho.29
Advanced MKs respond to Sdf-1 with reduced cellular Rho activity
(Figure 5E), a change that would reverse the proposed inhibition of
PPF by ROCK and phospho-MLC. Sdf-1 is enriched in marrow
sinusoids, where terminally mature MKs are known to home.13
Acting in concert with other local factors, Sdf-1 may attenuate MK
Rho activity and hence trigger PPF. Investigation of these possibili-
ties will improve understanding of homeostatic mechanisms that
maintain constant platelet numbers in the circulation while meeting
the body’s continuous demand to replenish cleared platelets.
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